
Kidney Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Kidney Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Drugs In Development, 2022, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.
Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.
Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Drugs In Development, 2022, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.
Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.
Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
154 Pages
- Introduction
- Global Markets Direct Report Coverage
- Kidney Transplant Rejection – Overview
- Kidney Transplant Rejection – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Kidney Transplant Rejection – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Kidney Transplant Rejection – Companies Involved in Therapeutics Development
- Alphamab Oncology
- AltruBio Inc
- Amgen Inc
- Amyndas Pharmaceuticals LLC
- Astellas Pharma Inc
- Bristol-Myers Squibb Co
- Cynata Therapeutics Ltd
- Eledon Pharmaceuticals Inc
- Enceladus Pharmaceuticals BV
- Hansa Biopharma AB
- Helocyte Biosciences Inc
- Hillhurst Biopharmaceuticals Inc
- Horizon Therapeutics Plc
- Idogen AB
- ITB-Med AB
- JN Biosciences LLC
- Junten Bio Co Ltd
- Kiniksa Pharmaceuticals Ltd
- Kronos Bio Inc
- Lignamed LLC
- Lyndra Therapeutics Inc.
- Medeor Therapeutics Inc
- MyeloRx LLC
- Nekonal Sarl
- NextCell Pharma AB
- OSE Immunotherapeutics
- Paranta Biosciences Ltd
- Pharmapraxis
- Rigel Pharmaceuticals Inc
- Sangamo Therapeutics Inc
- Sanofi
- Suzhou Regend Therapeutics Co Ltd
- SYnAbs SA
- Talaris Therapeutics Inc
- TolerogenixX GmbH
- Tonix Pharmaceuticals Holding Corp
- Xenothera SAS
- Zenas BioPharma (USA) LLC
- Kidney Transplant Rejection – Drug Profiles
- AbGn-168H – Drug Profile
- AMY-101 – Drug Profile
- AS-2521780 – Drug Profile
- AS-2553627 – Drug Profile
- ASP-0028 – Drug Profile
- belatacept – Drug Profile
- belatacept biosimilar – Drug Profile
- carfilzomib – Drug Profile
- Cellular Immunotherapy for Kidney Transplantation – Drug Profile
- CMVpp65 – Drug Profile
- dazodalibep – Drug Profile
- Drug for Kidney Transplant Rejection – Drug Profile
- FCR-001 – Drug Profile
- FCR-002 – Drug Profile
- fostamatinib disodium – Drug Profile
- FR-104 – Drug Profile
- Gene-Modified Cell Therapy for Kidney Transplant Rejection – Drug Profile
- GS-492429 – Drug Profile
- HBI-002 – Drug Profile
- HBI-137 – Drug Profile
- HuABC-2 – Drug Profile
- IDO-T – Drug Profile
- imlifidase – Drug Profile
- JB-101 – Drug Profile
- JB-201 – Drug Profile
- KPL-404 – Drug Profile
- LGM-1506 – Drug Profile
- LIS-1 – Drug Profile
- LO-TACT-1 anti-CD25 – Drug Profile
- lulizumab pegol – Drug Profile
- MDR-102 – Drug Profile
- MDR-103 – Drug Profile
- MIC-Lx – Drug Profile
- Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation – Drug Profile
- MRX-109 – Drug Profile
- prednisolone sodium phosphate – Drug Profile
- ProTrans – Drug Profile
- Recombinant Protein for Diabetic Nephropathy – Drug Profile
- REGEND-005 – Drug Profile
- Renal Transplant – Drug Profile
- rituximab biosimilar – Drug Profile
- siplizumab – Drug Profile
- sizavaleucel – Drug Profile
- Small Molecules for Liver Transplant Rejection and Kidney Transplant Rejection – Drug Profile
- Stem Cell Therapy for Kidney Transplant Rejection – Drug Profile
- sutimlimab – Drug Profile
- tacrolimus – Drug Profile
- tegoprubart – Drug Profile
- TNX-1500 – Drug Profile
- Triplex – Drug Profile
- TX-200 – Drug Profile
- ZB-003 – Drug Profile
- Kidney Transplant Rejection – Dormant Projects
- Kidney Transplant Rejection – Discontinued Products
- Kidney Transplant Rejection – Product Development Milestones
- Featured News & Press Releases
- Apr 20, 2022: Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Mar 28, 2022: Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients
- Mar 15, 2022: Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Mar 08, 2022: Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN
- Feb 26, 2022: Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Dec 29, 2021: Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
- Dec 14, 2021: Talaris Therapeutics presents high-resolution analysis of HLA mismatching in phase 2 trial in living donor kidney transplant
- Nov 04, 2021: Talaris Therapeutics provides first FREEDOM-1 phase 3 clinical update and presents additional phase 2 data and analyses at American Society of Nephrology Meeting
- Nov 04, 2021: Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
- Nov 01, 2021: Talaris begins Phase II clinical trial of allogeneic cell therapy
- Oct 28, 2021: Talaris Therapeutics announces upcoming presentations and investor conference call during American Society of Nephrology Meeting
- Oct 05, 2021: Eledon Pharmaceuticals announces upcoming presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
- Jul 26, 2021: Eledon Pharmaceuticals receives health Canada approval to commence human trials to evaluate AT-1501 in kidney transplantation
- Jun 04, 2021: BioStock: Idogen’s CEO on World Transplant Day and IDO T against organ rejection
- Jun 03, 2021: Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Kidney Transplant Rejection, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 11: Number of Products by Stage and Mechanism of Action, 2022
- Table 12: Number of Products by Stage and Route of Administration, 2022
- Table 13: Number of Products by Stage and Molecule Type, 2022
- Table 14: Kidney Transplant Rejection – Pipeline by Alphamab Oncology, 2022
- Table 15: Kidney Transplant Rejection – Pipeline by AltruBio Inc, 2022
- Table 16: Kidney Transplant Rejection – Pipeline by Amgen Inc, 2022
- Table 17: Kidney Transplant Rejection – Pipeline by Amyndas Pharmaceuticals LLC, 2022
- Table 18: Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc, 2022
- Table 19: Kidney Transplant Rejection – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 20: Kidney Transplant Rejection – Pipeline by Cynata Therapeutics Ltd, 2022
- Table 21: Kidney Transplant Rejection – Pipeline by Eledon Pharmaceuticals Inc, 2022
- Table 22: Kidney Transplant Rejection – Pipeline by Enceladus Pharmaceuticals BV, 2022
- Table 23: Kidney Transplant Rejection – Pipeline by Hansa Biopharma AB, 2022
- Table 24: Kidney Transplant Rejection – Pipeline by Helocyte Biosciences Inc, 2022
- Table 25: Kidney Transplant Rejection – Pipeline by Hillhurst Biopharmaceuticals Inc, 2022
- Table 26: Kidney Transplant Rejection – Pipeline by Horizon Therapeutics Plc, 2022
- Table 27: Kidney Transplant Rejection – Pipeline by Idogen AB, 2022
- Table 28: Kidney Transplant Rejection – Pipeline by ITB-Med AB, 2022
- Table 29: Kidney Transplant Rejection – Pipeline by JN Biosciences LLC, 2022
- Table 30: Kidney Transplant Rejection – Pipeline by Junten Bio Co Ltd, 2022
- Table 31: Kidney Transplant Rejection – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
- Table 32: Kidney Transplant Rejection – Pipeline by Kronos Bio Inc, 2022
- Table 33: Kidney Transplant Rejection – Pipeline by Lignamed LLC, 2022
- Table 34: Kidney Transplant Rejection – Pipeline by Lyndra Therapeutics Inc., 2022
- Table 35: Kidney Transplant Rejection – Pipeline by Medeor Therapeutics Inc, 2022
- Table 36: Kidney Transplant Rejection – Pipeline by MyeloRx LLC, 2022
- Table 37: Kidney Transplant Rejection – Pipeline by Nekonal Sarl, 2022
- Table 38: Kidney Transplant Rejection – Pipeline by NextCell Pharma AB, 2022
- Table 39: Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics, 2022
- Table 40: Kidney Transplant Rejection – Pipeline by Paranta Biosciences Ltd, 2022
- Table 41: Kidney Transplant Rejection – Pipeline by Pharmapraxis, 2022
- Table 42: Kidney Transplant Rejection – Pipeline by Rigel Pharmaceuticals Inc, 2022
- Table 43: Kidney Transplant Rejection – Pipeline by Sangamo Therapeutics Inc, 2022
- Table 44: Kidney Transplant Rejection – Pipeline by Sanofi, 2022
- Table 45: Kidney Transplant Rejection – Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022
- Table 46: Kidney Transplant Rejection – Pipeline by SYnAbs SA, 2022
- Table 47: Kidney Transplant Rejection – Pipeline by Talaris Therapeutics Inc, 2022
- Table 48: Kidney Transplant Rejection – Pipeline by TolerogenixX GmbH, 2022
- Table 49: Kidney Transplant Rejection – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Table 50: Kidney Transplant Rejection – Pipeline by Xenothera SAS, 2022
- Table 51: Kidney Transplant Rejection – Pipeline by Zenas BioPharma (USA) LLC, 2022
- Table 52: Kidney Transplant Rejection – Dormant Projects, 2022
- Table 53: Kidney Transplant Rejection – Dormant Projects, 2022 (Contd..1)
- Table 54: Kidney Transplant Rejection – Dormant Projects, 2022 (Contd..2)
- Table 55: Kidney Transplant Rejection – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Kidney Transplant Rejection, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.